Severe acne sufferers can now look forward to a new drug that is being developed by Allergan and Paratek Pharmaceuticals.
The drug, which uses the active ingredient sarecycline. Sarecycline is a once-daily, oral, narrow spectrum tetracycline-derived antibiotic with anti-inflammatory properties, which the companies will hope can gain a nod for moderate to severe acne in the community setting. The drug is also being studied in rosacea.
David Nicholson, chief global research and development officer for Allergan says, “The positive efficacy results observed in the pivotal phase 3 clinical trials indicate that sarecycline can be an effective treatment option for patients with moderate to severe acne.”
Results showed patients who took sarecycline once a day experienced less inflammatory lesions than those who didn’t. Clinical trials are still on-going, but Allergan released their plans to file a new drug application for their acne medication with the Food and Drug Administration sometime in 2017.